Plexision
Private Company
Funding information not available
Overview
Plexision is a privately held diagnostics company focused on personalizing care in transplantation and immunology through proprietary cellular biomarker tests. Its core technology measures antigen-specific white blood cells to predict risks such as organ rejection or viral reactivation. The company has achieved commercial traction with its FDA-approved Pleximmune test for pediatric liver/intestinal transplant rejection and a suite of lab-developed tests (LDTs) offered from its CLIA lab. Plexision also engages in custom biomarker R&D services for pharmaceutical partners, positioning itself at the intersection of diagnostics and drug development.
Technology Platform
Patented flow cytometry-based assays that measure antigen-specific white blood cells (T-cells) to assess cellular immune responses.
Opportunities
Risk Factors
Competitive Landscape
Plexision competes in the transplant diagnostics market against companies like CareDx (AlloMap, AlloSure) and Natera (Prospera) that use gene expression or donor-derived cell-free DNA to monitor rejection. Its cellular immunity approach is a differentiation, but it must prove clinical superiority or complementarity. In viral immunity testing, it faces competition from large clinical labs offering similar functional T-cell assays.